Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKesson
Merck
Colorcon
Boehringer Ingelheim
AstraZeneca
Medtronic

Last Updated: December 12, 2019

DrugPatentWatch Database Preview

Claims for Patent: 10,004,700

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Summary for Patent: 10,004,700
Title:More potent and less toxic formulations of epinephrine and methods of medical use
Abstract: The present invention provides pharmaceutical formulations of levorotatory-epinephrine, l-epinephrine, more potent and less toxic than existing pharmaceutical formulations of epinephrine, along with methods of producing and using these pharmaceutical formulations of l-epinephrine, including autoinjection for treating anaphylaxis.
Inventor(s): Taneja; Jugal K. (Tampa, FL)
Assignee:
Application Number:15/596,440
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 10,004,700
Patent Claims: 1. A method of treating allergic reaction, anaphylaxis, anaphylactic shock, or a combination thereof by an injection of at least one dosage of an injectable liquid pharmaceutical formulation of l-epinephrine sterile solution administered by a prefilled syringe containing said at least one dosage of said injectable liquid pharmaceutical formulation; said injectable liquid pharmaceutical formulation compounded in an aqueous solution and further including a tonicity agent; said injectable liquid pharmaceutical formulation containing up to 1.1 mg of l-epinephrine per prefilled syringe and having a pH between 2.8 and 3.3; said liquid pharmaceutical formulation including no more than about 6% d-epinephrine and no more than about 0.5% adrenalone at release, and no more than about 12% d-epinephrine and no more than about 0.5% adrenalone over a shelf-life of at least 12 months.

2. The method of claim 1 wherein said injectable liquid pharmaceutical formulation is compounded in an aqueous solution with up to 1.1 mg/mL l-epinephrine.

3. The method of claim 1 wherein said injectable liquid pharmaceutical formulation has a concentration of 1 mg per mL l-epinephrine.

4. The method of claim 1 wherein said injectable liquid pharmaceutical formulation is stored in a container with an inert gas prior to use.

5. The method of claim 1 wherein said injection is intramuscular or subcutaneous injection and is administered by a syringe assist device/autoinjector containing said prefilled syringe.

6. The method of claim 1 wherein said at least one dosage of an injectable liquid pharmaceutical formulation is approximately 0.15 mg l-epinephrine.

7. The method of claim 1 wherein said at least one dosage of an injectable liquid pharmaceutical formulation is approximately 0.30 mg l-epinephrine.

8. The method of claim 1 wherein said at least one dosage of an injectable liquid pharmaceutical formulation is approximately 0.50 mg l-epinephrine.

9. The method of claim 1 wherein said treating allergic reaction, anaphylaxis, anaphylactic shock, or a combination thereof is performed in patients with known or unknown sulfite-sensitivity or sulfite-allergy.

10. The method of claim 1 wherein said treating allergic reaction, anaphylaxis, anaphylactic shock, or a combination thereof is performed in patients with known or unknown sulfite-sensitivity or sulfite-allergy; said method further preventing the exacerbation, extension, or recurrence of allergic reaction, anaphylaxis, anaphylactic shock, or a combination thereof caused by sulfite-sensitivity or sulfite-allergy by avoiding additional sulfite-exposure.

11. A method of treating allergic reaction, anaphylaxis, anaphylactic shock, or a combination thereof in a patient with known or unknown sulfite-sensitivity or sulfite-allergy by an intramuscular or subcutaneous injection of at least one 0.15 mg to 0.50 mg l-epinephrine dosage of an injectable liquid pharmaceutical formulation of preservative-free and sulfite-free, 1 mg per mL l-epinephrine sterile solution administered by an autoinjector containing said at least one dosage of said injectable liquid pharmaceutical formulation; said injectable liquid pharmaceutical formulation compounded in an aqueous solution with up to 1.1 mg/mL l-epinephrine, and further including a tonicity agent; said injectable liquid pharmaceutical formulation having a pH between 2.8 and 3.3; said liquid pharmaceutical formulation having no more than 6.5% total impurities at release, and no more than 12.5% total impurities over a shelf-life of at least 12 months.

12. The method of claim 11 wherein said injectable liquid pharmaceutical formulation is stored in a container with an inert gas prior to use.

13. The said injectable liquid pharmaceutical formulation of claim 11 further having no more than 12.5% total impurities over a shelf-life of at least 15 months, including no more than 12% d-epinephrine and no more than 0.5% adrenalone.

14. A method of treating allergic reaction, anaphylaxis, anaphylactic shock, or a combination thereof that is caused by or exacerbated by sulfite exposure from sulfite-containing medications in a patient with known or unknown sulfite-sensitivity or sulfite-allergy; said method including an intramuscular or subcutaneous injection of at least one 0.15 mg to 0.50 mg l-epinephrine dosage of an injectable liquid pharmaceutical formulation of preservative-free and sulfite-free, 1 mg per mL l-epinephrine sterile solution administered by an autoinjector containing said at least one dosage of said injectable liquid pharmaceutical formulation; said injectable liquid pharmaceutical formulation compounded in an aqueous solution as approximately 1.0 to 1.06 mg/mL l-epinephrine, and further including a tonicity agent; said injectable liquid pharmaceutical formulation having a pH between 2.8 and 3.3; said liquid pharmaceutical formulation having no more than 6.5% total impurities at release, and no more than 12.5% total impurities over a shelf-life of at least 12 months.

15. A method of treating allergic reaction, anaphylaxis, anaphylactic shock, or a combination thereof that is caused by or exacerbated by sulfite exposure from a sulfite-containing epinephrine formulation administered by an autoinjector in a patient with known or unknown sulfite-sensitivity or sulfite-allergy; said method including an intramuscular or subcutaneous injection of at least one 0.15 mg to 0.50 mg l-epinephrine dosage of an injectable liquid pharmaceutical formulation of preservative-free and sulfite-free, 1 mg per mL l-epinephrine sterile solution administered by an autoinjector containing said at least one dosage of said injectable liquid pharmaceutical formulation; said injectable liquid pharmaceutical formulation compounded in an aqueous solution as approximately 1.0 to 1.06 mg/mL l-epinephrine, and further including a tonicity agent; said injectable liquid pharmaceutical formulation having a pH between 2.8 and 3.3; said liquid pharmaceutical formulation having no more than 6.5% total impurities at release, and no more than 12.5% total impurities over a shelf-life of at least 12 months.

16. An autoinjector containing at least one 0.15 mg to 0.50 mg l-epinephrine dosage of an injectable liquid pharmaceutical formulation of preservative-free and sulfite-free, 1 mg per mL l-epinephrine sterile solution; said injectable liquid pharmaceutical formulation compounded in an aqueous solution as approximately 1.0 to 1.06 mg/mL l-epinephrine, and further including a tonicity agent; said injectable liquid pharmaceutical formulation having a pH between 2.8 and 3.3; said liquid pharmaceutical formulation having no more than 6.5% total impurities at release, and no more than 12.5% total impurities over a shelf-life of at least 12 months; said autoinjector used for treating allergic reaction, anaphylaxis, anaphylactic shock, or a combination thereof in a patient with known or unknown sulfite-sensitivity or sulfite-allergy by providing an intramuscular or subcutaneous injection of said injectable liquid pharmaceutical formulation to said patient.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Colorcon
Harvard Business School
Boehringer Ingelheim
Dow
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.